You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Regional variation in the cost effectiveness of childhood hepatitis A immunization

JACOBS, R. JAKE MPA; GREENBERG, DAVID P. MD; KOFF, RAYMOND S. MD*; SAAB, SAMMY MD, MPH; MEYERHOFF, ALLEN S. MS

Pediatric Infectious Disease Journal:
Original Studies
Abstract

Background. Routine childhood hepatitis A immunization is recommended in regions with incidence rates twice the national average, but it may be cost-effective in a wider geographic area.

Objective. To evaluate the costs and benefits of potential hepatitis A immunization of healthy US children in regions with varying hepatitis A incidences.

Methods. We considered vaccination of the 2000 US birth cohort in states defined by historic hepatitis A incidence rates. Infections among potential vaccinees and their personal contacts were predicted from age 2 through 85 years. Net vaccination costs were estimated from health system and societal perspectives and were compared with life-years saved and quality-adjusted life years (QALYs) gained using a 3% discount rate.

Results. Nationally vaccination would prevent >75 000 cases of overt hepatitis A disease. Approximately two-thirds of health benefits would accrue to personal contacts rather than to vaccinees themselves. In states with incidence rates of ≥200%, 100 to 199%, 50 to 99% and <50% the national average, societal costs per QALY gained would be <$0, <$0, $13 800 and $63 000, respectively. Nationally vaccination would cost $9100 per QALY gained from the perspective of the health system and $1400 per QALY gained from society’s perspective. Results are most sensitive to vaccination costs and rates of disease transmission through personal contact.

Conclusion. Childhood hepatitis A vaccination is most cost-effective in areas with the highest incidence rates but would also meet accepted standards of economic efficiency in most of the US. A national immunization policy would prevent substantial morbidity and mortality, with cost effectiveness similar to that of other childhood immunizations.

Author Information

From Capitol Outcomes Research, Inc., Alexandria, VA (RJJ, ASM); the Department of Pediatrics, University of Pittsburgh School of Medicine, and Division of Allergy, Immunology and Infectious Diseases, Children’s Hospital of Pittsburgh, Pittsburgh, PA (DPG); the Division of Gastroenterology, University of Massachusetts Medical School, Worcester, MA (RSK); and the Departments of Medicine and Surgery, University of California Los Angeles, Los Angeles, CA (SS).

Accepted for publication July 16, 2003.

*Current address: Roche Laboratories, Nutley, NJ.

Address for reprints: R. Jake Jacobs, Research Director, Capitol Outcomes Research, Inc., 6188 Old Franconia Road, Alexandria, VA 22310. Fax 703-922-1853; E-mail Jake.Jacobs@CapitolOutcomesResearch.com.

© 2003 Lippincott Williams & Wilkins, Inc.